Presentation
Patrice Hugo, Ph.D. | February 12, 2019

Key Central Laboratory Capabilities to Enable Successful Immuno-Oncology Clinical Development

Trends and recommendations in laboratory selection
This presentation provides the laboratory and operational requirements of immuno-oncology trials, and explores trends in I-O drug development and biomarker usage. Q2 Solutions presented at the Immuno-Oncology 360° 2019 conference as part of a plenary session.

Q2 Solutions has a unique role in immuno-oncology drug development, providing clinical laboratory services and utilizing early engagement and continuous communication with partners and clients to drive higher quality results.

Download this presentation to learn more.

Speaker:
Patrice Hugo, PhD, Chief Scientific Officer

Related Services:
Q2 Solutions Biomarker Services

Providing tools and experience to maximize your biomarker strategy

The Power of the Central Laboratory for Immuno-Oncology Drug Development

New Opportunities for Immuno-oncology Clinical Development Programs through T cell/B cell Repertoire Profiling

Immune repertoire profiling provides better outcomes for immuno-oncology development programs

Read More